Dr. Gilbert on Precision Medicine in Glioblastoma

Mark R. Gilbert, MD
Published: Monday, Nov 23, 2015



Mark R. Gilbert, MD, senior investigator, chief, Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, discusses the use of precision medicine in treating patients with glioblastoma.

Gilbert explains that there are complications in the various components of precision medicine and by breaking them down, there may be a greater understanding in treating these patients. These components include tumor heterogeneity, he adds.

Research conducted within The Cancer Genome Atlas has shown that there is differentiation within various cells of one tumor. Therefore, making informed treatment decisions based on original diagnostic tissue should not be done, Gilbert says.

<<< View more from the 2015 SNO Meeting



Mark R. Gilbert, MD, senior investigator, chief, Neuro-Oncology Branch, National Cancer Institute, Center for Cancer Research, discusses the use of precision medicine in treating patients with glioblastoma.

Gilbert explains that there are complications in the various components of precision medicine and by breaking them down, there may be a greater understanding in treating these patients. These components include tumor heterogeneity, he adds.

Research conducted within The Cancer Genome Atlas has shown that there is differentiation within various cells of one tumor. Therefore, making informed treatment decisions based on original diagnostic tissue should not be done, Gilbert says.

<<< View more from the 2015 SNO Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x